Investor Alert: Deadline Approaching to Join ARS Pharmaceuticals, Inc. (SPRY) Class Action - Contact Levi & Korsinsky
NEW YORK CITY, NY / ACCESS Newswire / August 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) securities.
If you suffered a loss on your ARS Pharmaceuticals investment and would like to explore a potential recovery under the federal securities laws, Learn about ARS Pharmaceuticals Class Action or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against ARS Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 9, 2026 and June 24, 2026.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark.
On June 24, 2026, after the market closed, ARS published a press release announcing that the Company did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027.
On this news, investors and analysts reacted immediately to ARS's revelation. The price of ARS's common stock declined from a closing market price of $10.54 per share on June 24, 2026 to $8.02 per share on June 25, 2026, a decline of over 23.9% in the span of just a single day.
WHAT'S NEXT? If you purchased ARS Pharmaceuticals stock during the relevant time frame - even if you still hold your shares, learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP